Lipomedix Pharmaceuticals Ltd. announces the FDA clearance of its IND application to launch a randomized Phase 2b clinical trial of Promitil for the treatment of patients with previously treated metastatic colorectal cancer (Oct 2018).
Lipomedix Pharmaceuticals Ltd. announces the Israeli Ministry of Health clearance to launch a Phase 1b clinical trial of Promitil in combination with external beam radiotherapy in patients with advanced cancer requiring palliative radiotherapy for inoperable primary tumors or metastatic disease. The study (Liporad-18) will be launched soon and conducted by investigators in two Medical Centers in Israel (Nov 2018).
May 2018: Lipomedix received the approval of a new USPT Patent Application (#9937261) for the combined use of Promitil with Radiotherapy entitled “Combination Therapy Comprising a Liposomal Prodrug of Mitomycin C and Radiotherapy”
July-2016: News release from UNC-Chapel Hill Cancer Center on a recently published joint paper with Lipomedix on our product Promitil and radiotherapy (http://unclineberger.org/news/wang-radiation)
May 2016: Lipomedix received a 2million shekel grant from the Israel Chief Scientist Office for the funding of the project “Development of Promitil a pegylated liposomal MMC- prodrug”
Poster entitled “Clinical and pharmacokinetic study with a lipidic prodrug of mitomycin-c entrapped in liposomes in metastatic colorectal cancer patients” will be presented at the American Association for Cancer Research (AACR), annual meeting, Monday Apr 1, 2019 8:00 AM - 12:00 PM, Atlanta, Georgia, US
Poster entitled “Liposome co-encapsulation of doxorubicin and a prodrug of mitomycin-c for pharmacological optimization of combination chemotherapy” presented at the International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) meeting, November 8-9, 2018, Amsterdam, the Netherlands
Poster entitled “A dual drug formulation of pegylated liposomes with co-encapsulated doxorubicin and mitomycin c lipid-based prodrug for chemotherapy of cancer” presented at the ICRS meeting, October 7-9, 2018, Maalot, Israel
Dr. Alberto Gabizon, CEO and Chief Scientist of Lipomedix, lectured at the 3rd Global Bioequivalence Harmonization Initiative Conference which took place in Amsterdam, April 12-13, 2018 (http://www.eufeps.org/conferences/3rd_GBHI) on "Liposome-based therapeutics: Impact of formulation on pharmacokinetics and pharmacodynamics"
Poster entitled “A Multidrug Formulation of Pegylated Liposomes with Co-Encapsulated Alendronate, Doxorubicin, and Mitomycin-C Lipid–Based Prodrug for Chemo-Immunotherapy of Cancer” presented at the ICRS meeting, September 14-16, 2016, Maalot, Israel
Poster entitled “A Phase 1B Study of Pegylated Liposomal Mitomycin-C Prodrug with or without Capecitabine and Bevacizumab in Third Line Chemotherapy of Colorectal Cancer” presented at the ESMO meeting, October 10-13, 2016, Copenhagen, Denmark
Poster entitled “Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (Promitil®)” presented at Nano Israel Conference, February 22-23, Tel Aviv University, Israel
Lipomedix is seeking additional funding from private investors or investment groups for clinical studies leading to registration of Promitil® in US and world markets for advanced metastatic colo-rectal cancer, and for further developing its pipeline. Prospective investors are invited to meet with the Company’s management team to discuss an investment in the Company.